|
Age, median (range)
|
44 (19–70)
|
|
Gender, male
|
70 (59.8%)
|
|
Laboratory findings at diagnosis
|
|
Leukocyte count (×109/L)
|
2.68 (0.4–112.0)
|
|
Leukocytes count at peak (×109/L)
|
16.6 (0.4–112.0)
|
|
Hemoglobin (g/dL)
|
8.9 (4.0–15.0)
|
|
Platelet (×109/L)
|
33.0 (5.0–163.0)
|
|
Lactate dehydrogenase (LDH, U/L)
|
692 (250–4070)
|
|
Prothrombin time (PT, %)
|
63.0 (35.0–101.0%)
|
|
Partial thromboplastin time (aPTT, s)
|
28.0 (20–45)
|
|
Fibrinogen (mg/dL)
|
134.0 (31.0–500.0)
|
|
Antithrombin III (%)
|
94.0 (49.0–150.0)
|
|
D-dimer (mg/L)
|
17.0 (1.0–36.0)
|
|
Sanz criteria
|
|
High
|
64 (54.7%)
|
|
Intermediate
|
19 (16.2%)
|
|
Low
|
34 (29.1%)
|
|
Karyotype
|
|
Normal karyotype
|
5 (4.3%)
|
|
t(15;17) alone
|
79 (67.5%)
|
|
t(15;17) with 1 additional karyotype
|
20 (17.1%)
|
|
t(15;17) with ≥2 additional karyotype
|
13 (11.1%)
|
|
PML-RARa subtype
|
|
BCR1
|
85 (72.6%)
|
|
BCR3
|
32 (27.4%)
|
|
FLT3 mutation
|
|
No FLT3 mutation
|
86 (73.5%)
|
|
FLT3-ITD
|
25 (21.4%)
|
|
FLT3-TKD
|
6 (5.1%)
|
|
WT1 (copies/104
ABL), median (range)
|
|
At diagnosis (n = 117)
|
18330 (20.0–236160.0)
|
|
Post-induction (n = 117)
|
63.9 (4.9–2360.0)
|
|
Post 1st consolidation (n = 117)
|
66.2 (1.1–2320.0)
|
|
Post 2nd consolidation (n = 117)
|
80.1 (1.3–2110.0)
|
|
Post 3rd consolidation (n = 117)
|
71.9 (10.8–808.0)
|
|
aPost-maintenance 3 months (n = 117)
|
70.0 (6.0–5520.0)
|
|
aPost-maintenance 1 year (n = 87)
|
57.5 (10.0–1630.0)
|
|
aPost-maintenance 2 year (n = 62)
|
54.4 (10.0–500.0)
|
|
At relapse (n = 16)
|
239.5 (77.1–34910.0)
|
|
Leukapheresis at initial treatment
|
20 (17.1%)
|
|
Differentiation syndrome
|
21 (17.9%)
|
|
Hematological complete response
|
|
After induction
|
115 (98.3%)
|
|
After 2nd induction
|
2 (1.7%)
|
|
Complete molecular response (CMR)
|
|
After induction
|
68 (58.1%)
|
|
After 2nd induction
|
2 (1.7%)
|
|
After 1st consolidation
|
42 (35.9%)
|
|
After 2nd consolidation
|
5 (4.3%)
|
